🔎 Trials Near Me

Beranda › Tumor Wilms › Texas

Uji klinis Tumor Wilms di Texas

6 studi untuk Tumor Wilms mencari peserta di lokasi di Texas.

Kota di Texas

Teks studi resmi (Bahasa Inggris)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • dan 10 lainnya
Menerima pesertaFase 2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • Texas Children's Hospital, Houston
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT04715191

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

  • Cook Children's Health Care System (Data Collection Only), Fort Worth
Menerima pesertaFase 2
12 Months · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT05985161

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

  • Houston Methodist Hospital, Houston
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 3 Nov 2025 · NCT06198296

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.